Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Arbutus Biopharma Corp | General Counsel and CCO | Common Shares | 95.1K | $220K | $2.31 | Feb 1, 2024 | Direct |
Arbutus Biopharma Corp | General Counsel and CCO | Stock Option (Right to Buy) | 381K | Feb 1, 2024 | Direct | ||
Nabriva Therapeutics plc | General Counsel and Corp Sec | Stock Appreciation Right | 63.2K | Aug 11, 2022 | Direct | ||
Nabriva Therapeutics plc | General Counsel and Corp Sec | Phantom Shares | 31.6K | Aug 11, 2022 | Direct | ||
Nabriva Therapeutics plc | General Counsel and Corp Sec | Restricted Stock Units | 0 | Aug 11, 2022 | Direct | ||
Nabriva Therapeutics plc | General Counsel and Corp Sec | Share Options | 0 | Aug 11, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ABUS | Arbutus Biopharma Corp | Feb 1, 2024 | 2 | $0 | 4 | Feb 5, 2024 | General Counsel and CCO |
ABUS | Arbutus Biopharma Corp | Jul 10, 2023 | 1 | $0 | 4 | Jul 12, 2023 | General Counsel and CCO |
ABUS | Arbutus Biopharma Corp | Jul 10, 2023 | 0 | $0 | 3 | Jul 12, 2023 | General Counsel and CCO |
NBRV | Nabriva Therapeutics plc | Aug 11, 2022 | 4 | $0 | 4 | Aug 15, 2022 | General Counsel and Corp Sec |
NBRV | Nabriva Therapeutics plc | Dec 27, 2021 | 1 | $4.13K | 4 | Dec 28, 2021 | General Counsel and Corp Sec |
NBRV | Nabriva Therapeutics plc | Sep 30, 2021 | 1 | $0 | 4 | Oct 1, 2021 | General Counsel and Corp Sec |
NBRV | Nabriva Therapeutics plc | Sep 3, 2021 | 0 | $0 | 3 | Sep 15, 2021 | General Counsel and Corp Sec |
NBRV | Nabriva Therapeutics plc | Jan 28, 2021 | 2 | $0 | 4 | Feb 1, 2022 | General Counsel and Corp Sec |